Supriya Lifescience Limited (SUPRIYA) AI Stock Analysis

Supriya Lifescience Limited

(NSE:SUPRIYA)

Select Model

Rating:68.8Neutral

Price Target:INR 950.00▲(12.27% Upside)

Action:reiterated

Date:08/19/26

The stock’s score is driven primarily by strong financial performance, combining solid growth, high profitability, and a very low-risk balance sheet despite some margin compression and past free cash flow volatility. Technicals currently show subdued momentum and higher volatility, indicating near-term pressure even as the longer-term trend remains constructive. A P/E in the low 30s with minimal dividend support leaves valuation only moderately attractive and reduces the overall score despite the company’s solid financial foundation.

Positive Factors

Revenue GrowthStrong multi-year revenue expansion indicates recovering demand and broader commercial traction across the API portfolio. Continued top-line growth can improve manufacturing utilization, support operating leverage, and provide a durable base for reinvestment in products and capacity.

Negative Factors

Free Cash Flow VolatilityThe history of negative free cash flow shows that cash generation has not been consistently predictable, potentially reflecting periods of heavy investment or working-capital swings. Although the recent rebound is strong, future expansion may continue to produce uneven internally available cash.

Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)

Market Cap: INR 68.19B
Dividend Yield: 0.12%
Average Volume (3M): 18.73K
Price to Earnings (P/E): 34.4
Beta (1Y): 1.37
Revenue Growth: 28.14%
EPS Growth: 11.38%
Country: India
Employees: 607
Sector: General
Sector Strength: 55
Industry: Medical - Pharmaceuticals

Supriya Lifescience Limited Business Overview & Revenue Model

Company Description

Supriya Lifescience Limited engages in the research and development, manufacture, and sale of bulk drugs and pharmaceutical chemicals worldwide. The company offers active pharmaceuticals ingredients in antihistamine, anti-allergic, anti-asthmatic, de...

How the Company Makes Money

Supriya Lifescience primarily makes money by manufacturing and selling active pharmaceutical ingredients (APIs) to customers that formulate and market finished pharmaceutical products. Revenue is earned from (1) API sales across its product portfolio...

Supriya Lifescience Limited Financial Statement Overview

Summary

Strong revenue and profit growth, high margins, and a very conservative balance sheet (low debt, growing equity and assets) support a high score, though margin compression and historically volatile free cash flow temper it slightly.

Income Statement

83Very Positive

Balance Sheet

90Very Positive

Cash Flow

74Positive

Financial statement breakdown
Breakdown	TTM	Mar 2026	Mar 2025	Mar 2024	Mar 2023	Mar 2022
Income Statement
Total Revenue	8.75B	8.28B	6.96B	5.57B	4.51B	5.19B
Gross Profit	5.63B	4.49B	3.84B	2.80B	2.20B	2.89B
EBITDA	3.01B	3.05B	2.71B	1.84B	1.37B	2.22B
Net Income	1.98B	2.09B	1.88B	1.19B	898.57M	1.52B
Balance Sheet
Total Assets	0	13.57B	11.12B	9.21B	8.20B	7.35B
Cash, Cash Equivalents and Short-Term Investments	788.67M	788.67M	791.54M	749.56M	1.58B	2.25B
Total Debt	0	54.35M	53.80M	54.88M	224.68M	274.15M
Total Liabilities	-11.98B	1.59B	1.16B	1.06B	1.21B	1.19B
Stockholders Equity	11.98B	11.98B	9.97B	8.15B	6.99B	6.16B
Cash Flow
Free Cash Flow	133.16M	429.88M	101.89M	-323.48M	-422.13M	-111.03M
Operating Cash Flow	555.65M	1.95B	1.73B	1.13B	661.87M	488.01M
Investing Cash Flow	-304.29M	-1.88B	-1.52B	-1.74B	-1.24B	-598.22M
Financing Cash Flow	-10.75M	-79.93M	-82.33M	-223.59M	-102.76M	1.50B

Supriya Lifescience Limited Technical Analysis

Technical Analysis SentimentNegative

Last Price846.20

Price Trends

50DMA874.63Negative

100DMA882.42Negative

200DMA784.91Positive

Market Momentum

MACD-13.30Positive

RSI43.97Neutral

STOCH56.49Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Negative. The current price of 846.20 is below the 20-day moving average (MA) of 868.19, below the 50-day MA of 874.63, and above the 200-day MA of 784.91, indicating a neutral trend. The MACD of -13.30 indicates Positive momentum. The RSI at 43.97 is Neutral, neither overbought nor oversold. The STOCH value of 56.49 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUPRIYA.

Supriya Lifescience Limited Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

IN:SUPRIYA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IN:BLUEJET	69Neutral	INR 95.47B	37.24	―	0.24%	-27.51%	-34.49%
IN:SUPRIYA	69Neutral	INR 68.10B	34.37	―	0.12%	28.14%	11.38%
IN:ZOTA	59Neutral	INR 40.31B	-39.62	―	0.08%	68.95%	-55.82%
IN:DCAL	56Neutral	INR 22.76B	33.34	―	―	-20.86%	-34.51%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
IN:ONESOURCE	48Neutral	INR 179.26B	-10420.00	―	―	10.66%	-104.59%
IN:PANACEABIO	47Neutral	INR 19.17B	-270.04	―	―	10.26%	-162.02%

* General Sector Average

Performance Comparison

IN:SUPRIYA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
IN:SUPRIYA	Supriya Lifescience Limited	846.20	62.38	7.96%
IN:BLUEJET	Blue Jet Healthcare Limited	504.40	-168.94	-25.09%
IN:DCAL	Dishman Carbogen Amcis Ltd.	145.15	-146.50	-50.23%
IN:PANACEABIO	Panacea Biotec Limited	312.95	-119.10	-27.57%
IN:ZOTA	Zota Health Care Ltd.	1328.80	-244.92	-15.56%
IN:ONESOURCE	OneSource Specialty Pharma Limited	1563.25	-312.15	-16.64%

Supriya Lifescience Limited Corporate Events

Supriya Lifescience Schedules Virtual Investor Meet, Posts Presentation Online

Sep 20, 2026

Supriya Lifescience Limited has announced that its officials will hold a virtual group meeting with analysts and institutional investors on Friday, September 25, 2026, from 11:00 a.m. to 12:00 noon. The company has also made its latest investor prese...

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 08, 2026

Supriya Lifescience Limited AI Stock Analysis